{"id":108,"date":"2014-09-17T13:21:04","date_gmt":"2014-09-17T13:21:04","guid":{"rendered":"https:\/\/www.glenmarkpharma.cz\/?p=108"},"modified":"2023-09-08T08:28:04","modified_gmt":"2023-09-08T08:28:04","slug":"vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii","status":"publish","type":"post","link":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/","title":{"rendered":"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed"},"content":{"rendered":"

Antagonista TRPA1 vyroben\u00fd spole\u010dnost\u00ed Glenmark, prvn\u00ed ve sv\u00e9 kategorii, p\u0159inesl pozitivn\u00ed data ve studii f\u00e1ze 2a u\u00a0pacient\u016f s\u00a0bolestivou diabetickou neuropati\u00ed<\/p>\n

17. z\u00e1\u0159\u00ed 2014:<\/b> Spole\u010dnost Glenmark Pharmaceuticals dnes ozn\u00e1mila, \u017ee jej\u00ed antagonista TRPA1 (Transient Receptor Potential Ankyrin 1), prvn\u00ed sv\u00e9ho druhu na sv\u011bt\u011b, p\u0159inesl pozitivn\u00ed data ve studii f\u00e1ze Phase 2a, dvojit\u011b zaslepen\u00e9, placebem kontrolovan\u00e9 multicentrick\u00e9 studii na prok\u00e1z\u00e1n\u00ed vhodnosti koncepce, kter\u00e1 byla provedena u\u00a0pacient\u016f z\u00a0Evropy a\u00a0Indie.<\/p>\n

P\u0159\u00edpravek byl dob\u0159e sn\u00e1\u0161en bez zn\u00e1mek ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f na CNS \u010di jin\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f l\u00e9\u010diva.<\/p>\n

Patrick Keohane, odborn\u00fd \u0159editel spole\u010dnosti Glenmark, uvedl: \u201eDiabetick\u00e1 neuropatie je t\u011b\u017eko zvl\u00e1dnuteln\u00fd chronick\u00fd klinick\u00fd stav s\u00a0omezen\u00fdmi mo\u017enostmi l\u00e9\u010dby. Tato prvn\u00ed data o\u00a0\u00fa\u010dinnosti a\u00a0bezpe\u010dnosti l\u00e9ku, perifern\u011b \u00fa\u010dinkuj\u00edc\u00ed nov\u00e9 terapie, jsou povzbudiv\u00e1 a\u00a0Glenmark se chyst\u00e1 je\u0161t\u011b do konce tohoto fisk\u00e1ln\u00edho roku p\u0159ihl\u00e1sit studii dal\u0161\u00ed f\u00e1zi studie u\u00a0pacient\u016f s\u00a0neuropatickou bolest\u00ed. Toto ozn\u00e1men\u00ed tak\u00e9 znovu potvrzuje na\u0161i glob\u00e1ln\u00ed vedouc\u00ed pozici v\u00a0oblasti v\u00fdvoje nov\u00fdch mo\u017enost\u00ed l\u00e9\u010dby bolesti\u201d.<\/strong><\/p>\n

V\u00a0koment\u00e1\u0159i k\u00a0t\u011bmto v\u00fdsledk\u016fm Dr. Michael Buschle, v\u011bdeck\u00fd \u0159editel a\u00a0vedouc\u00ed odd\u011blen\u00ed biologick\u00fdch l\u00e9k\u016f Glenmark Pharmaceuticals uvedl: \u201cJe to velmi slibn\u00e9 a\u00a0zkouman\u00fd l\u00e9k m\u016f\u017ee b\u00fdt u\u017eite\u010dn\u00fd pro \u0159adu r\u016fzn\u00fdch indikac\u00ed, co\u017e se chyst\u00e1me prozkoumat \u201d.<\/p>\n

O\u00a0spole\u010dnosti Glenmark Pharmaceuticals Ltd<\/h3>\n

Glenmark Pharmaceuticals Ltd. (GPL) je glob\u00e1ln\u00ed v\u00fdzkumn\u00e1 integrovan\u00e1 farmaceutick\u00e1 firma \u0159ad\u00edc\u00ed se mezi 80 nejv\u011bt\u0161\u00edch farmaceutick\u00fdch a\u00a0biotechnick\u00fdch spole\u010dnost\u00ed sv\u011bta z\u00a0pohledu tr\u017eeb podle po\u0159ad\u00ed SCRIP100. Spole\u010dnost Glenmark p\u0159isp\u011bla nejv\u011bt\u0161\u00edm d\u00edlem k\u00a0objevu nov\u00fdch molekul NCE a\u00a0NBE. Glenmark m\u00e1 n\u011bkolik t\u011bchto molekul v\u00a0r\u016fzn\u00fdch f\u00e1z\u00edch klinick\u00e9ho v\u00fdvoje s\u00a0prim\u00e1rn\u00edm zam\u011b\u0159en\u00edm na z\u00e1n\u011bty, bolest a\u00a0onkologii. Spole\u010dnost se v\u00fdznamnou m\u011brou pod\u00edl\u00ed na prodeji zna\u010dkov\u00fdch l\u00e9k\u016f v\u00a0rozvojov\u00fdch zem\u00edch v\u010detn\u011b Indie. Jej\u00ed pobo\u010dka Glenmark Generics Limited uspokojuje po\u017eadavky trhu Spojen\u00fdch st\u00e1t\u016f a\u00a0Z\u00e1padn\u00ed Evropy.<\/p>\n

Dal\u0161\u00ed informace poskytnou:<\/b><\/p>\n

Jason D\u2019Souza \/ Rajdeep Barooah \u00b7 Glenmark, Bombaj, Indie \u00b7 Tel: [+91-22-] 40189919 \/ 40189993 \u00b7 <\/span>Email:\u00a0<\/span>corpcomm@glenmarkpharma.com<\/a><\/p>\n

Kontakt pro mo\u017enost zakoupen\u00ed licence:<\/b><\/p>\n

Jeff Lange \u00b7 Glenmark, NJ, US \u00b7 Tel: 1-201-684-8000\/8003 \u00b7 <\/span>Email:\u00a0<\/span>jeffl@glenmarkpharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Antagonista TRPA1 vyroben\u00fd spole\u010dnost\u00ed Glenmark, prvn\u00ed ve sv\u00e9 kategorii, p\u0159inesl pozitivn\u00ed data ve studii f\u00e1ze 2a u\u00a0pacient\u016f s\u00a0bolestivou diabetickou neuropati\u00ed<\/p>\n","protected":false},"author":2,"featured_media":72,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aktuality"],"acf":[],"yoast_head":"\nV\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\" \/>\n<meta property=\"og:locale\" content=\"cs_CZ\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM\" \/>\n<meta property=\"og:description\" content=\"Antagonista TRPA1 vyroben\u00fd spole\u010dnost\u00ed Glenmark, prvn\u00ed ve sv\u00e9 kategorii, p\u0159inesl pozitivn\u00ed data ve studii f\u00e1ze 2a u\u00a0pacient\u016f s\u00a0bolestivou diabetickou neuropati\u00ed\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\" \/>\n<meta property=\"og:site_name\" content=\"Glenmark VM\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-17T13:21:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-08T08:28:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1295\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ji\u0159\u00ed \u017ditn\u00edk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napsal(a)\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ji\u0159\u00ed \u017ditn\u00edk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Odhadovan\u00e1 doba \u010dten\u00ed\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\"},\"author\":{\"name\":\"Ji\u0159\u00ed \u017ditn\u00edk\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422\"},\"headline\":\"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed\",\"datePublished\":\"2014-09-17T13:21:04+00:00\",\"dateModified\":\"2023-09-08T08:28:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\"},\"wordCount\":435,\"image\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg\",\"articleSection\":[\"Aktuality\"],\"inLanguage\":\"cs\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\",\"url\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\",\"name\":\"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM\",\"isPartOf\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg\",\"datePublished\":\"2014-09-17T13:21:04+00:00\",\"dateModified\":\"2023-09-08T08:28:04+00:00\",\"author\":{\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422\"},\"inLanguage\":\"cs\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"cs\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage\",\"url\":\"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg\",\"contentUrl\":\"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg\",\"width\":1920,\"height\":1295},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/#website\",\"url\":\"https:\/\/www.glenmarkpharma.cz\/gp\/\",\"name\":\"Glenmark VM\",\"description\":\"A new way for a new world\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.glenmarkpharma.cz\/gp\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"cs\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422\",\"name\":\"Ji\u0159\u00ed \u017ditn\u00edk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"cs\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g\",\"caption\":\"Ji\u0159\u00ed \u017ditn\u00edk\"},\"url\":\"https:\/\/www.glenmarkpharma.cz\/gp\/author\/spravceadmin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/","og_locale":"cs_CZ","og_type":"article","og_title":"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM","og_description":"Antagonista TRPA1 vyroben\u00fd spole\u010dnost\u00ed Glenmark, prvn\u00ed ve sv\u00e9 kategorii, p\u0159inesl pozitivn\u00ed data ve studii f\u00e1ze 2a u\u00a0pacient\u016f s\u00a0bolestivou diabetickou neuropati\u00ed","og_url":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/","og_site_name":"Glenmark VM","article_published_time":"2014-09-17T13:21:04+00:00","article_modified_time":"2023-09-08T08:28:04+00:00","og_image":[{"width":1920,"height":1295,"url":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg","type":"image\/jpeg"}],"author":"Ji\u0159\u00ed \u017ditn\u00edk","twitter_card":"summary_large_image","twitter_misc":{"Napsal(a)":"Ji\u0159\u00ed \u017ditn\u00edk","Odhadovan\u00e1 doba \u010dten\u00ed":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#article","isPartOf":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/"},"author":{"name":"Ji\u0159\u00ed \u017ditn\u00edk","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422"},"headline":"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed","datePublished":"2014-09-17T13:21:04+00:00","dateModified":"2023-09-08T08:28:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/"},"wordCount":435,"image":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage"},"thumbnailUrl":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg","articleSection":["Aktuality"],"inLanguage":"cs"},{"@type":"WebPage","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/","url":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/","name":"V\u00fdzkum a v\u00fdvoj Antagonista TRPA1 pro l\u00e9\u010dbu bolesti u pacient\u016f s diabetickou neuropati\u00ed - Glenmark VM","isPartOf":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage"},"image":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage"},"thumbnailUrl":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg","datePublished":"2014-09-17T13:21:04+00:00","dateModified":"2023-09-08T08:28:04+00:00","author":{"@id":"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422"},"inLanguage":"cs","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/"]}]},{"@type":"ImageObject","inLanguage":"cs","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/vyzkum-a-vyvoj-antagonista-trpa1-pro-lecbu-bolesti-u-pacientu-s-diabetickou-neuropatii\/#primaryimage","url":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg","contentUrl":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-content\/uploads\/sites\/2\/2022\/05\/image-red.jpg","width":1920,"height":1295},{"@type":"WebSite","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/#website","url":"https:\/\/www.glenmarkpharma.cz\/gp\/","name":"Glenmark VM","description":"A new way for a new world","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.glenmarkpharma.cz\/gp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"cs"},{"@type":"Person","@id":"https:\/\/www.glenmarkpharma.cz\/gp\/#\/schema\/person\/59736c891c4e4caf67799903183ea422","name":"Ji\u0159\u00ed \u017ditn\u00edk","image":{"@type":"ImageObject","inLanguage":"cs","@id":"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fbd44978f4c91979e1f11309a5f061a9a587ab08dc488f6546b4ad737dc6c643?s=96&d=mm&r=g","caption":"Ji\u0159\u00ed \u017ditn\u00edk"},"url":"https:\/\/www.glenmarkpharma.cz\/gp\/author\/spravceadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/posts\/108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/comments?post=108"}],"version-history":[{"count":2,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/posts\/108\/revisions"}],"predecessor-version":[{"id":494,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/posts\/108\/revisions\/494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/media\/72"}],"wp:attachment":[{"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/media?parent=108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/categories?post=108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.glenmarkpharma.cz\/gp\/wp-json\/wp\/v2\/tags?post=108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}